In
this study, we aimed to investigate the influence of ginsenoside
Rg5 (Rg5) on gut microbiota in diabetic db/db mice. Our data indicated
that Rg5 not only improved the symptoms of hyperglycemia, repaired
intestinal barrier function, and relieved metabolic endotoxemia-related
inflammation but also reversed gut microbiota dysbiosis in the colon
with significantly decreased Firmicutes/Bacteroidetes ratios. More importantly, the effects of Rg5 were further confirmed
by partial changes in the gut microbiota induced by broad-spectrum
antibiotics. These findings indicated that Rg5 dramatically decreased
the abundance of Firmicutes and Verrucomicrobia at the phylum level and increased the abundance of Bacteroidetes and Proteobacteria in diabetic db/db mice. Altogether,
our findings, for the first time, demonstrate that Rg5 may be used
as a beneficial probiotic agent that reverses gut microbiota dysbiosis
and diabetes-associated metabolic disorders in the context of type
2 diabetes mellitus.